0001209191-22-035059.txt : 20220608 0001209191-22-035059.hdr.sgml : 20220608 20220608164519 ACCESSION NUMBER: 0001209191-22-035059 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220606 FILED AS OF DATE: 20220608 DATE AS OF CHANGE: 20220608 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Murray Mark Anthony CENTRAL INDEX KEY: 0001791443 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39112 FILM NUMBER: 221004004 MAIL ADDRESS: STREET 1: 202 CARNEGIE CENTER STREET 2: SUITE 109 CITY: PRINCETON STATE: NJ ZIP: 08540 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Oyster Point Pharma, Inc. CENTRAL INDEX KEY: 0001720725 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 811030955 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 202 CARNEGIE CENTER STREET 2: SUITE 109 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: (609) 382-9032 MAIL ADDRESS: STREET 1: 202 CARNEGIE CENTER STREET 2: SUITE 109 CITY: PRINCETON STATE: NJ ZIP: 08540 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-06-06 0 0001720725 Oyster Point Pharma, Inc. OYST 0001791443 Murray Mark Anthony C/O OYSTER POINT PHARMA, INC. 202 CARNEGIE CENTER, SUITE 109 PRINCETON NJ 08540 1 0 0 0 Common Stock 2022-06-06 4 A 0 3573 0.00 A 122086 D Stock Option (Right to Buy) 3.63 2022-06-06 4 A 0 5359 0.00 A 2032-06-05 Common Stock 5359 5359 D Represents a grant of restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The shares underlying the RSU will vest on June 6, 2023, but will vest fully on the date of the next annual stockholder meeting held after the date of grant if not fully vested on such date, in each case, subject to the Reporting Person's continuous service to the Issuer as a director through each such date. The shares underlying the option vest as to one-twelfth (1/12th) of the shares on July 6, 2022 and monthly thereafter on the same day of the month as the grant date, in each case, subject to the Reporting Person's continuous service to the Issuer as a director through each such date. /s/ Brandon Fenn, Attorney-in-Fact 2022-06-08